DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
TOREFORANT
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Histamine H4 receptor antagonist
TOREFORANT
×
Maximum Phase:
2
First Approval:
None
UNII:
U6LA7G393X
Molecule Type:
Small molecule
Molecular Formula:
C23H32N6
Molecular Weight:
392.55
AlogP:
4.48
PSA:
69.73
HBD:
2.0
HBA:
#RotB:
6.0
Source:
IMO-8400
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
IMO-8400
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ARX-788
2
Unknown
Investigational
Unknown
Unknown
Breast Neoplasms
Unknown
ARX-788
×
Maximum Phase:
2
First Approval:
None
UNII:
B2KH16FA7H
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ABEDITEROL
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Pulmonary Disease, Chronic Obstructive
Beta-2 adrenergic receptor agonist
ABEDITEROL
×
Maximum Phase:
2
First Approval:
None
UNII:
QXA167CM6F
Molecule Type:
Small molecule
Molecular Formula:
C25H30F2N2O4
Molecular Weight:
460.52
AlogP:
4.23
PSA:
94.58
HBD:
4.0
HBA:
#RotB:
13.0
Source:
APRICOXIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms
Cyclooxygenase-2 inhibitor
APRICOXIB
×
Maximum Phase:
2
First Approval:
None
UNII:
5X5HB3VZ3Z
Molecule Type:
Small molecule
Molecular Formula:
C19H20N2O3S
Molecular Weight:
356.45
AlogP:
3.5
PSA:
74.32
HBD:
1.0
HBA:
#RotB:
5.0
Source:
ABC294640
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
ABC294640
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EVATANEPAG
2
Small molecule
Investigational
Unknown
Unknown
Tibial Fractures
Prostanoid EP2 receptor agonist
EVATANEPAG
×
Maximum Phase:
2
First Approval:
None
UNII:
L266R6E31E
Molecule Type:
Small molecule
Molecular Formula:
C25H28N2O5S
Molecular Weight:
468.58
AlogP:
4.23
PSA:
96.8
HBD:
1.0
HBA:
#RotB:
9.0
Source:
(+/-)NICOTINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
(+/-)NICOTINE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C10H14N2
Molecular Weight:
162.24
AlogP:
1.85
PSA:
16.13
HBD:
0.0
HBA:
#RotB:
1.0
Source:
L-SULFORAPHANE
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Unknown
L-SULFORAPHANE
×
Maximum Phase:
2
First Approval:
None
UNII:
7J94TPZ10L
Molecule Type:
Small molecule
Molecular Formula:
C6H11NOS2
Molecular Weight:
177.29
AlogP:
1.25
PSA:
29.43
HBD:
0.0
HBA:
#RotB:
5.0
Source:
CD24FC
2
Unknown
Investigational
Unknown
Unknown
Melanoma; Neoplasms; Severe Acute Respiratory Syndrome
Heat shock 70 kDa protein 1A/1B inhibitor
CD24FC
×
Maximum Phase:
2
First Approval:
None
UNII:
FN12T66RMN
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KOS-1584
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Tubulin stabiliser
KOS-1584
×
Maximum Phase:
2
First Approval:
None
UNII:
82481G197K
Molecule Type:
Small molecule
Molecular Formula:
C27H39NO5S
Molecular Weight:
489.68
AlogP:
5.04
PSA:
96.72
HBD:
2.0
HBA:
#RotB:
2.0
Source:
VALATEGRAST
2
Small molecule
Investigational
Unknown
Unknown
Asthma
Unknown
VALATEGRAST
×
Maximum Phase:
2
First Approval:
None
UNII:
06DM4KX7JG
Molecule Type:
Small molecule
Molecular Formula:
C30H32Cl3N3O4
Molecular Weight:
604.96
AlogP:
6.43
PSA:
87.74
HBD:
2.0
HBA:
#RotB:
12.0
Source:
DIMETHYLAMINOETHANOL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DIMETHYLAMINOETHANOL
×
Maximum Phase:
2
First Approval:
None
UNII:
2N6K9DRA24
Molecule Type:
Small molecule
Molecular Formula:
C4H11NO
Molecular Weight:
89.14
AlogP:
-0.46
PSA:
23.47
HBD:
1.0
HBA:
#RotB:
2.0
Source:
LUCATUMUMAB
2
Antibody
Investigational
Unknown
Unknown
Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma
Tumor necrosis factor receptor superfamily member 5 antagonist
LUCATUMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
P0EP9VFC4R
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GRANOTAPIDE
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
GRANOTAPIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
PSZ2YGB0DK
Molecule Type:
Small molecule
Molecular Formula:
C39H37F3N2O8
Molecular Weight:
718.73
AlogP:
6.48
PSA:
128.31
HBD:
1.0
HBA:
#RotB:
13.0
Source:
EGFR
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
EGFR
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
L 756423
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Unknown
L 756423
×
Maximum Phase:
2
First Approval:
None
UNII:
862SGU1BRL
Molecule Type:
Small molecule
Molecular Formula:
C39H48N4O5
Molecular Weight:
652.84
AlogP:
4.22
PSA:
118.28
HBD:
4.0
HBA:
#RotB:
11.0
Source:
DEXISOMETHEPTENE MUCATE
2
Small molecule
Investigational
Unknown
Unknown
Tension-Type Headache
Unknown
DEXISOMETHEPTENE MUCATE
×
Maximum Phase:
2
First Approval:
None
UNII:
G5E8S36F0N
Molecule Type:
Small molecule
Molecular Formula:
C24H48N2O8
Molecular Weight:
492.65
AlogP:
2.34
PSA:
12.03
HBD:
1.0
HBA:
#RotB:
4.0
Source:
RASEGLURANT
2
Small molecule
Investigational
Unknown
Unknown
Gastroesophageal Reflux; Migraine Disorders
Metabotropic glutamate receptor 5 modulator
RASEGLURANT
×
Maximum Phase:
2
First Approval:
None
UNII:
66UCJ8Z8L1
Molecule Type:
Small molecule
Molecular Formula:
C15H13FN2
Molecular Weight:
240.28
AlogP:
2.82
PSA:
38.91
HBD:
1.0
HBA:
#RotB:
0.0
Source:
ABC-294640
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Pancreatic Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Prostatic Neoplasms, Castration-Resistant
Sphingosine kinase 2 inhibitor
ABC-294640
×
Maximum Phase:
2
First Approval:
None
UNII:
DRG21OQ517
Molecule Type:
Small molecule
Molecular Formula:
C23H25ClN2O
Molecular Weight:
380.92
AlogP:
4.89
PSA:
41.99
HBD:
1.0
HBA:
#RotB:
4.0
Source:
AZD8683
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Muscarinic acetylcholine receptor M3 antagonist
AZD8683
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ANTI-PSGL-1 ANTIBODY SELK2
2
Unknown
Investigational
Unknown
Unknown
Venous Thromboembolism
Unknown
ANTI-PSGL-1 ANTIBODY SELK2
×
Maximum Phase:
2
First Approval:
None
UNII:
FR57BKG0QJ
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CR 1447
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Androgen Receptor agonist
CR 1447
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GI-6301
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
GI-6301
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HANK
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
HANK
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RADIPRODIL
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia; Spasms, Infantile
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
RADIPRODIL
×
Maximum Phase:
2
First Approval:
None
UNII:
5XGC17ZKUF
Molecule Type:
Small molecule
Molecular Formula:
C21H20FN3O4
Molecular Weight:
397.41
AlogP:
2.68
PSA:
95.41
HBD:
2.0
HBA:
#RotB:
3.0
Source:
DAR-0100A
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DAR-0100A
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
A-002
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
A-002
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
APIMOSTINEL
2
Protein
Investigational
Unknown
Unknown
Depressive Disorder, Major; Schizophrenia
Glutamate [NMDA] receptor partial agonist
APIMOSTINEL
×
Maximum Phase:
2
First Approval:
None
UNII:
TTT1F11FZB
Molecule Type:
Protein
Molecular Formula:
C25H37N5O6
Molecular Weight:
503.6
AlogP:
-1.36
PSA:
179.29
HBD:
5.0
HBA:
#RotB:
9.0
Source:
PIROMELATINE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Sleep Initiation and Maintenance Disorders
Melatonin receptor agonist
PIROMELATINE
×
Maximum Phase:
2
First Approval:
None
UNII:
S3UN2146K9
Molecule Type:
Small molecule
Molecular Formula:
C17H16N2O4
Molecular Weight:
312.33
AlogP:
2.1
PSA:
84.33
HBD:
2.0
HBA:
#RotB:
5.0
Source:
XTL-6865
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
XTL-6865
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PEGDINETANIB
2
Protein
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Glioblastoma
Vascular endothelial growth factor receptor 2 inhibitor
PEGDINETANIB
×
Maximum Phase:
2
First Approval:
None
UNII:
SSB56T0M0L
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRATOSARTAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Solute carrier family 22 member 12 inhibitor
PRATOSARTAN
×
Maximum Phase:
2
First Approval:
None
UNII:
66VLQ6E6DL
Molecule Type:
Small molecule
Molecular Formula:
C25H26N6O
Molecular Weight:
426.52
AlogP:
4.64
PSA:
89.35
HBD:
1.0
HBA:
#RotB:
6.0
Source:
PD-217014
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome; Pain
Unknown
PD-217014
×
Maximum Phase:
2
First Approval:
None
UNII:
K2T93E812G
Molecule Type:
Small molecule
Molecular Formula:
C11H19NO2
Molecular Weight:
197.28
AlogP:
1.31
PSA:
52.32
HBD:
1.0
HBA:
#RotB:
3.0
Source:
SETRUSUMAB
2
Antibody
Investigational
Unknown
Unknown
Hypophosphatasia; Kidney Diseases; Osteogenesis Imperfecta
Sclerostin inhibitor
SETRUSUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
FPW3780T3E
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
143
144
145
146
147
148
149
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA